menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Nektar to Evaluate Rezpegaldesleukin in New Type 1 Diabetes

    PR NEWSWIRE

    Nektar`s Fast Track Designation for Rezpegaldesleukin in Dermatitis

    PR NEWSWIRE

    Ampersand Completes Acquisition of Nektar’s PEG Business

    PR NEWSWIRE

    Nektar Therapeutics Presents NKTR-422 Preclinical Data at ACR

    PR NEWSWIRE

    Nektar Presents Late-Breaking Phase 2 Results of NKTR-255 at SITC

    PR NEWSWIRE

    Nektar extends cash runway with $90M manufacturing plant sale

    FIERCE PHARMA

    Nektar Reaches Agreement to Sell PEGylation Manufacturing Business

    PR NEWSWIRE

    Nektar Publishes Ph 1B For Rezpegaldesleukin In Skin Diseases

    PR NEWSWIRE

    Nektar Therapeutics Reports Second Quarter 2024 Financial Results

    PR NEWSWIRE

    Nektar`s NKTR-0165 TNFR2 Agonist Preclinical Data At EULAR

    PR NEWSWIRE

    Nektar Therapeutics Reports First Quarter 2024 Financial Results

    PR NEWSWIRE

    Biolojic: Nektar Options TNFR2 AI-Designed Antibody

    GLOBENEWSWIRE

    Nektar Announces Initiation of Phase 2b Study Evaluating Rezpegaldesleuki

    PR NEWSWIRE

    Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGX

    PR NEWSWIRE

    Nektar Management to Present at the TD Cowen 44th Annual Health Care Conference

    PR NEWSWIRE

    Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2023

    PR NEWSWIRE

    Nektar Management To Present at 42nd Annual J.P. Morgan Healthcare Conference

    PR NEWSWIRE

    Nektar and Collaborators Present Data on NKTR-255 in Presentation

    PR NEWSWIRE

    Nektar Therapeutics Reports Third Quarter 2023 Financial Results

    PR NEWSWIRE

    Nektar to Announce Financial Results for the Third Quarter 2023

    PR NEWSWIRE

    Nektar Presents New Responder Data for Rezpegaldesleukin

    PR NEWSWIRE

    Nektar Announces New Clinical Study Collaboration with Cellular Biomedicine

    PR NEWSWIRE

    Nektar Announces Promising Data from Phase 1b Study of Rezpegaldesleukin

    PR NEWSWIRE

    Nektar Therapeutics Reports Second Quarter 2023 Financial Results

    PR NEWSWIRE

    Nektar CEO slams Lilly’s ‘egregious error,` laments lost time

    FIERCE BIOTECH

    Nektar Therapeutics sues Eli Lilly over autoimmune disease treatment

    REUTERS

    Nektar Announces Promising New and Corrected Rezpegaldesleukin Efficacy Data

    PR NEWSWIRE

    Nektar to Participate in Fireside Chat at Goldman 44th Healthcare Conference

    PR NEWSWIRE

    Nektar Therapeutics Reports First Quarter 2023 Financial Results

    PR NEWSWIRE

    Lilly hands rights to immunology med back to Nektar

    FIERCE BIOTECH

    Nektar Therapeutics Announces It Will Regain Full Rights to Rezpegaldesleukin

    PR NEWSWIRE

    Nektar Announces Strategic Reprioritization & Cost Restructuring Plan

    PR NEWSWIRE

    Nektar Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results

    PR NEWSWIRE

    Nektar’s latest PhII flop threatens to unravel $400M-plus deal with Eli Lilly

    ENDPTS

    Nektar Therapeutics` autoimmune disease drug fails mid-stage study

    REUTERS

    Nektar pins comeback hopes on Lilly collab and cancer combinator

    FIERCE BIOTECH

    Nektar Announces Poster Presentations at ASH Annual Meeting

    PRNEWSWIRE

    Nektar Therapeutics to Host Investor & Analyst Event on December 12th

    PRNEWSWIRE

    Nektar Presents Preclinical Data PEGylated Interferon Gamma Program, NKTR-288

    PRNEWSWIRE

    Nektar and Collaborators Announce Publication in Blood Advances Data NKTR-255

    PRNEWSWIRE

    Sanofi reveals setback for cancer drug acquired in Synthorx buyout 

    BIOPHARMADIVE

    UPDATE: Record scratch—Nektar and PureTech`s merger talks are off

    FIERCEBIOTECH

    PureTech confirms negotiations for a possible Nektar merger

    PHARMAPHORUM

    Nektar`s plans to buy PureTech confirmed

    FIERCEBIOTECH

    Nektar Therapeutics Presents Data for Rezpegaldesleukin (LY3471851)

    PRNEWSWIRE

    Nektar and Collaborators Announce Preclinical Publication of Data for NKTR-255

    PRNEWSWIRE

    Nektar Therapeutics Reports Second Quarter 2022 Financial Results

    PRNEWSWIRE

    Nektar to Announce Financial Results for the Second Quarter 2022 on Thursday

    PRNEWSWIRE

    Nektar Announces Promotion of Jillian B. Thomsen to Senior VP & CFO

    PRNEWSWIRE

    In wake of IL-2 shutdown, Nektar lets go of 500+ staffers as it promises

    ENDPTS

    Nektar Therapeutics Announces Strategic Reorganization Plan & Corporate Outlook

    PRESS RELEASE

    Nektar & Collaborators Present Preclinical Data on NKTR-255, a Novel IL-15

    PRNEWSWIRE

    BMS, Nektar end $3.6B I-O program after 2 more late-stage flops

    FIERCEBIOTECH

    Nektar, BMS drug combination fails in late-stage melanoma trial

    BIOPHARMADIVE

    Nektar Tx Reports Q4 and Year-End 2021 Financial Results

    PRNEWSWIRE

    Exelixis Initiates Phase 1b Trial of XL092 with Immuno-oncology Therapies

    BUSINESSWIRE

    Nektar Presents Clinical Data for NKTR-255 in Hematologic Malignancies

    PRNEWSWIRE

    Nektar Therapeutics Appoints Diana M. Brainard

    PRNEWSWIRE

    Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors

    PRESS RELEASE

    RayzeBio Appoints Mary Tagliaferri to its Board of Directors and more

    BUSINESSWIRE

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.